Luciano Agati, Francesca De Maio, Maria Pina Madonna, Flavia Celani, Stefania Funaro, Gianni Tonti
Journal: Echocardiography (Mount Kisco, N.Y.) 2003;19(7 Pt 2):627-34
PMID: 12401139
After many years of study and research, the noninvasive assessment of myocardial perfusion by echo contrast agents is becoming a clinical reality. The fast technological progress of echocardiographic imaging and the approval for human use in Europe and the United States of some first and second generation contrast agents explains the growing interest in this new methodology. Recently, a new second generation contrast agent, SonoVue, made of microbubbles stabilized by phospholipids and containing sulphur hexafluoride, has been introduced on the European market. We describe the role of intravenous myocardial contrast echocardiography with second-generation contrast agents such as SonoVue in the tailored reperfusion strategies in acute myocardial infarction.
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.